Mizuho analyst Vikram Malhotra lowered the firm’s price target on Healthpeak Properties (DOC) to $24 from $25 and keeps an Outperform rating on the shares. The firm says that despite healthcare real estate investment trusts’ outperformance in fiscal 2024, it continues to like the subsector into fiscal 2025, but feels “some rotation is warranted. Mizuho reiterates a positive stance on senior housing and shifted to neutral from positive on the skilled nursing facility group. It recommends rotating into life sciences as it sees venture funding improving through the year.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties Highlights 2024 Guidance at REITworld
- Healthpeak Properties raises FY24 FFO view to $1.79-$1.81 from $1.80-$1.82
- Healthpeak Properties Engages Investors Amid Market Challenges
- Healthpeak Properties price target raised to $25 from $24 at Baird
- Healthpeak Properties Reports Strong Q3 2024 Results